Koers Bachem Holding AG Swiss Exchange
Aandelen
BANB
CH0012530207
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 620 mln. 685 mln. 636 mln. | Omzet 2025 * | 811 mln. 896 mln. 832 mln. | Marktkapitalisatie | 6,02 mld. 6,65 mld. 6,18 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 127 mln. 140 mln. 130 mln. | Nettowinst (verlies) 2025 * | 160 mln. 177 mln. 164 mln. | EV/omzet 2024 * | 9,61 x |
Nettoliquiditeiten 2024 * | 64,89 mln. 71,68 mln. 66,6 mln. | Nettoschuld 2025 * | 74,85 mln. 82,67 mln. 76,81 mln. | EV/omzet 2025 * | 7,52 x |
K/w-verhouding 2024 * |
50,1
x | K/w-verhouding 2025 * |
38
x | Werknemers | 2.006 |
Dividendrendement 2024 * |
1,07% | Dividendrendement 2025 * |
1,16% | Vrij verhandelbaar | 94,31% |
Recentste transcriptie over Bachem Holding AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Meier
CEO | Chief Executive Officer | 56 | 01-01-19 |
Alain Schaffter
DFI | Director of Finance/CFO | 47 | 01-02-21 |
Ralph Schönleber
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-03 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Peter Grogg
BRD | Director/Board Member | 82 | - |
Kuno Sommer
CHM | Chairman | 68 | 25-04-12 |
Director/Board Member | 51 | 13-04-11 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.15% | 18 M€ | +3,01% | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,69% | 47,86 mld. | |
+46,90% | 41,42 mld. | |
-3,46% | 40,66 mld. | |
-6,20% | 28,92 mld. | |
+9,17% | 25,55 mld. | |
-20,42% | 19,27 mld. | |
+0,17% | 12,15 mld. | |
+28,07% | 12,14 mld. | |
-1,24% | 11,99 mld. |